;PMID: 8145767
;source_file_1946.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..164] = [t:45..164]
;2)section:[e:168..232] = [t:168..232]
;3)section:[e:236..407] = [t:236..407]
;4)sentence:[e:411..605] = [t:411..605]
;5)sentence:[e:606..798] = [t:606..798]
;6)sentence:[e:800..1108] = [t:800..1108]
;7)sentence:[e:1109..1508] = [t:1109..1508]
;8)sentence:[e:1510..1679] = [t:1510..1679]
;9)sentence:[e:1680..1927] = [t:1680..1927]
;10)sentence:[e:1928..2035] = [t:1928..2035]
;11)section:[e:2035..2069] = [t:2035..2069]
;12)section:[e:2073..2117] = [t:2073..2117]

;section 0 Span:0..39
;Mol Endocrinol. 1993 Dec;7(12):1617-24.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..14] Endocrinol) (.:[14..15] .)
        (CD:[16..20] 1993) (CC:[21..27] Dec;7-LRB-) (CD:[27..29] 12)
        (-RRB-:[29..30] -RRB-) (CD:[30..35] :1617) (::[35..36] -)
        (CD:[36..38] 24) (.:[38..39] .)))

;sentence 1 Span:45..164
;Functional domains of human aromatase cytochrome P450 characterized by linear
; alignment and site-directed mutagenesis.
;[73..98]:cyp450:"aromatase cytochrome P450"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[45..55] Functional) (NNS:[56..63] domains))
      (PP (IN:[64..66] of)
        (NP (JJ:[67..72] human)
           (NN:[73..82] aromatase) (NN:[83..93] cytochrome) (NN:[94..98] P450))))
    (VP (VBN:[99..112] characterized)
      (NP (-NONE-:[112..112] *))
      (PP (IN:[113..115] by)
        (NP-LGS
          (NP (JJ:[116..122] linear) (NN:[124..133] alignment))
          (CC:[134..137] and)
          (NP
            (ADJP (NN:[138..142] site) (HYPH:[142..143] -)
                  (VBN:[143..151] directed))
            (NN:[152..163] mutagenesis)))))
    (.:[163..164] .)))

;section 2 Span:168..232
;Amarneh B, Corbin CJ, Peterson JA, Simpson ER, Graham-Lorence S.
(SEC
  (FRAG (NNP:[168..175] Amarneh) (NNP:[176..177] B) (,:[177..178] ,)
        (NNP:[179..185] Corbin) (NNP:[186..188] CJ) (,:[188..189] ,)
        (NNP:[190..198] Peterson) (NNP:[199..201] JA) (,:[201..202] ,)
        (NNP:[203..210] Simpson) (NN:[211..213] ER) (,:[213..214] ,)
        (NNP:[215..221] Graham) (HYPH:[221..222] -) (NNP:[222..229] Lorence)
        (NNP:[230..232] S.)))

;section 3 Span:236..407
;Cecil H. and Ida Green Center for Reproductive Biology Sciences, Department
;of  Obstetrics-Gynecology, University of Texas Southwestern Medical Center,
;Dallas  75235-9051.
(SEC
  (FRAG (NNP:[236..241] Cecil) (NNP:[242..244] H.) (CC:[245..248] and)
        (NNP:[249..252] Ida) (NNP:[253..258] Green) (NNP:[259..265] Center)
        (IN:[266..269] for) (NNP:[270..282] Reproductive)
        (NNP:[283..290] Biology) (NNP:[291..299] Sciences) (,:[299..300] ,)
        (NNP:[301..311] Department) (IN:[312..314] of)
        (NNP:[316..326] Obstetrics) (HYPH:[326..327] -)
        (NNP:[327..337] Gynecology) (,:[337..338] ,) (NNP:[339..349] University)
        (IN:[350..352] of) (NNP:[353..358] Texas) (NNP:[359..371] Southwestern)
        (NNP:[372..379] Medical) (NNP:[380..386] Center) (,:[386..387] ,)
        (NNP:[388..394] Dallas) (CD:[396..401] 75235) (HYPH:[401..402] -)
        (CD:[402..406] 9051) (.:[406..407] .)))

;sentence 4 Span:411..605
;The relationship of function to structure of aromatase cytochrome P450 
;(P450arom; the product of the CYP19 gene) has been examined by means of
;sequence  alignment and site-directed mutagenesis.
;[456..481]:cyp450:"aromatase cytochrome P450"
;[484..492]:cyp450:"P450arom"
;[513..518]:cyp450:"CYP19"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[411..414] The) (NN:[415..427] relationship))
      (PP (IN:[428..430] of)
        (NP (NN:[431..439] function)))
      (PP (TO:[440..442] to)
        (NP (NN:[443..452] structure)))
      (PP (IN:[453..455] of)
        (NP
          (NP (NN:[456..465] aromatase) (NN:[466..476] cytochrome)
              (NN:[477..481] P450))
          (NP (-LRB-:[483..484] -LRB-)
            (NP (NN:[484..492] P450arom))
            (::[492..493] ;)
            (NP
              (NP (DT:[494..497] the) (NN:[498..505] product))
              (PP (IN:[506..508] of)
                (NP (DT:[509..512] the) (NN:[513..518] CYP19)
                    (NN:[519..523] gene))))
            (-RRB-:[523..524] -RRB-)))))
    (VP (VBZ:[525..528] has)
      (VP (VBN:[529..533] been)
        (VP (VBN:[534..542] examined)
          (NP-1 (-NONE-:[542..542] *))
          (PP-MNR (IN:[543..545] by)
            (NP
              (NP (NN:[546..551] means))
              (PP (IN:[552..554] of)
                (NP
                  (NP (NN:[555..563] sequence) (NN:[565..574] alignment))
                  (CC:[575..578] and)
                  (NP
                    (ADJP (NN:[579..583] site) (HYPH:[583..584] -)
                          (VBN:[584..592] directed))
                    (NN:[593..604] mutagenesis)))))))))
    (.:[604..605] .)))

;sentence 5 Span:606..798
;Comparison has been made between the  sequence of P450arom and the two
;soluble bacterial cytochrome P450 isoforms,  whose three-dimensional
;structure has been determined (P450BM3 and P450cam).
;[656..664]:cyp450:"P450arom"
;[695..719]:cyp450:"cytochrome P450 isoforms"
;[777..784]:cyp450:"P450BM3"
;[789..796]:cyp450:"P450cam"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[606..616] Comparison))
      (PP-3 (-NONE-:[616..616] *ICH*)))
    (VP (VBZ:[617..620] has)
      (VP (VBN:[621..625] been)
        (VP (VBN:[626..630] made)
          (NP-2 (-NONE-:[630..630] *))
          (PP-3 (IN:[631..638] between)
            (NP
              (NP (DT:[639..642] the) (NN:[644..652] sequence))
              (PP (IN:[653..655] of)
                (NP
                  (NP (NN:[656..664] P450arom))
                  (CC:[665..668] and)
                  (NP
                    (NP (DT:[669..672] the) (CD:[673..676] two)
                        (JJ:[677..684] soluble) (JJ:[685..694] bacterial)
                      
                      (NML (NN:[695..705] cytochrome) (NN:[706..710] P450))
                      (NNS:[711..719] isoforms))
                    (,:[719..720] ,)
                    (SBAR
                      (WHNP-1
                        (NP (WP$:[722..727] whose))
                        (ADJP (CD:[728..733] three) (HYPH:[733..734] -)
                              (JJ:[734..745] dimensional))
                        (NN:[746..755] structure))
                      (S
                        (NP-SBJ-1 (-NONE-:[755..755] *T*))
                        (VP (VBZ:[756..759] has)
                          (VP (VBN:[760..764] been)
                            (VP (VBN:[765..775] determined)
                              (NP-1 (-NONE-:[775..775] *))
                              (PRN (-LRB-:[776..777] -LRB-)
                                (NP (NN:[777..784] P450BM3) (CC:[785..788] and)
                                    (NN:[789..796] P450cam))
                                (-RRB-:[796..797] -RRB-)))))))))))))))
    (.:[797..798] .)))

;sentence 6 Span:800..1108
;From this comparison, it appears that although there is a similarity of
;overall  structure in cytochromes P450, there is enough significant
;difference in the  regions involved in substrate recognition and substrate
;binding that residues  believed to be involved, even in the known structures,
;must be tested.
;[894..910]:cyp450:"cytochromes P450"
;[979..988]:substance:"substrate"
;[1005..1014]:substance:"substrate"
(SENT
  (S
    (PP (IN:[800..804] From)
      (NP (DT:[805..809] this) (NN:[810..820] comparison)))
    (,:[820..821] ,)
    (NP-SBJ (PRP:[822..824] it))
    (VP (VBZ:[825..832] appears)
      (SBAR (IN:[833..837] that)
        (S
          (SBAR-ADV (IN:[838..846] although)
            (S
              (NP-SBJ (EX:[847..852] there))
              (VP (VBZ:[853..855] is)
                (NP-PRD
                  (NP (DT:[856..857] a) (NN:[858..868] similarity))
                  (PP (IN:[869..871] of)
                    (NP (JJ:[872..879] overall) (NN:[881..890] structure))))
                (PP (IN:[891..893] in)
                  (NP (NNS:[894..905] cytochromes) (NN:[906..910] P450))))))
          (,:[910..911] ,)
          (NP-SBJ (EX:[912..917] there))
          (VP (VBZ:[918..920] is)
            (NP-PRD
              (NP (JJ:[921..927] enough) (JJ:[928..939] significant)
                  (NN:[940..950] difference)
                (SBAR-3 (-NONE-:[950..950] *ICH*)))
              (PP-LOC (IN:[951..953] in)
                (NP
                  (NP (DT:[954..957] the) (NNS:[959..966] regions))
                  (VP (VBN:[967..975] involved)
                    (NP (-NONE-:[975..975] *))
                    (PP-CLR (IN:[976..978] in)
                      (NP
                        (NP (NN:[979..988] substrate)
                            (NN:[989..1000] recognition))
                        (CC:[1001..1004] and)
                        (NP (NN:[1005..1014] substrate)
                            (NN:[1015..1022] binding)))))))
              (SBAR-3 (IN:[1023..1027] that)
                (S
                  (NP-SBJ-2
                    (NP (NNS:[1028..1036] residues))
                    (VP (VBN:[1038..1046] believed)
                      (S
                        (NP-SBJ-1 (-NONE-:[1046..1046] *))
                        (VP (TO:[1047..1049] to)
                          (VP (VB:[1050..1052] be)
                            (VP (VBN:[1053..1061] involved)
                              (NP-1 (-NONE-:[1061..1061] *))))))))
                  (,:[1061..1062] ,)
                  (PP-LOC
                    (ADVP (RB:[1063..1067] even))
                    (IN:[1068..1070] in)
                    (NP (DT:[1071..1074] the) (VBN:[1075..1080] known)
                        (NNS:[1081..1091] structures)))
                  (,:[1091..1092] ,)
                  (VP (MD:[1093..1097] must)
                    (VP (VB:[1098..1100] be)
                      (VP (VBN:[1101..1107] tested)
                        (NP-2 (-NONE-:[1107..1107] *))))))))))))
    (.:[1107..1108] .)))

;sentence 7 Span:1109..1508
;With this  in mind, we have generated a detailed alignment of P450arom,
;including the  definition of putative alpha-helices and beta-sheets based on
;comparison of the  alignments of P450BM3 and P450cam, generated from their
;three-dimensional  structure, and have made mutations in regions we believe
;to be involved in  substrate recognition at the solvent surface and
;orientation in the heme pocket.
;[1171..1179]:cyp450:"P450arom"
;[1291..1298]:cyp450:"P450BM3"
;[1303..1310]:cyp450:"P450cam"
;[1428..1437]:substance:"substrate"
(SENT
  (S
    (PP (IN:[1109..1113] With)
      (NP
        (NP (DT:[1114..1118] this))
        (PP (IN:[1120..1122] in)
          (NP (NN:[1123..1127] mind)))))
    (,:[1127..1128] ,)
    (NP-SBJ (PRP:[1129..1131] we))
    (VP
      (VP (VBP:[1132..1136] have)
        (VP (VBN:[1137..1146] generated)
          (NP
            (NP (DT:[1147..1148] a) (VBN:[1149..1157] detailed)
                (NN:[1158..1167] alignment))
            (PP (IN:[1168..1170] of)
              (NP (NN:[1171..1179] P450arom))))
          (,:[1179..1180] ,)
          (PP (VBG:[1181..1190] including)
            (NP
              (NP
                (NP (DT:[1191..1194] the) (NN:[1196..1206] definition))
                (PP (IN:[1207..1209] of)
                  (NP
                    (NP
                      (ADJP-2 (JJ:[1210..1218] putative))
                      (SYM:[1219..1224] alpha) (HYPH:[1224..1225] -)
                       (NNS:[1225..1232] helices))
                    (CC:[1233..1236] and)
                    (NP
                      (ADJP-2 (-NONE-:[1236..1236] *P*))
                      (SYM:[1237..1241] beta) (HYPH:[1241..1242] -)
                       (NNS:[1242..1248] sheets)))))
              (VP (VBN:[1249..1254] based)
                (NP (-NONE-:[1254..1254] *))
                (PP-CLR (IN:[1255..1257] on)
                  (NP
                    (NP (NN:[1258..1268] comparison))
                    (PP (IN:[1269..1271] of)
                      (NP
                        (NP
                          (NP (DT:[1272..1275] the)
                              (NNS:[1277..1287] alignments))
                          (PP (IN:[1288..1290] of)
                            (NP (NN:[1291..1298] P450BM3) (CC:[1299..1302] and)
                                (NN:[1303..1310] P450cam))))
                        (,:[1310..1311] ,)
                        (VP (VBN:[1312..1321] generated)
                          (NP (-NONE-:[1321..1321] *))
                          (PP (IN:[1322..1326] from)
                            (NP (PRP$:[1327..1332] their)
                              (ADJP (CD:[1333..1338] three)
                                    (HYPH:[1338..1339] -)
                                    (JJ:[1339..1350] dimensional))
                              (NN:[1352..1361] structure)))))))))))))
      (,:[1361..1362] ,) (CC:[1363..1366] and)
      (VP (VBP:[1367..1371] have)
        (VP (VBN:[1372..1376] made)
          (NP (NNS:[1377..1386] mutations))
          (PP-LOC (IN:[1387..1389] in)
            (NP
              (NP (NNS:[1390..1397] regions))
              (SBAR
                (WHNP-1 (-NONE-:[1397..1397] 0))
                (S
                  (NP-SBJ (PRP:[1398..1400] we))
                  (VP (VBP:[1401..1408] believe)
                    (S
                      (NP-SBJ-1 (-NONE-:[1408..1408] *))
                      (VP (TO:[1409..1411] to)
                        (VP (VB:[1412..1414] be)
                          (VP (VBN:[1415..1423] involved)
                            (NP-1 (-NONE-:[1423..1423] *))
                            (PP-CLR (IN:[1424..1426] in)
                              (NP
                                (NP
                                  (NP (NN:[1428..1437] substrate)
                                      (NN:[1438..1449] recognition))
                                  (PP (IN:[1450..1452] at)
                                    (NP (DT:[1453..1456] the)
                                        (NN:[1457..1464] solvent)
                                        (NN:[1465..1472] surface))))
                                (CC:[1473..1476] and)
                                (NP
                                  (NP (NN:[1477..1488] orientation))
                                  (PP (IN:[1489..1491] in)
                                    (NP (DT:[1492..1495] the)
                                        (NN:[1496..1500] heme)
                                        (NN:[1501..1507] pocket))))))))))))))))))
    (.:[1507..1508] .)))

;sentence 8 Span:1510..1679
;We have mutated F116 and F134 to determine if they are present in the heme 
;pocket, and Q225 and L228 to determine if they are a part of the substrate 
;recognition loop.
;[1651..1660]:substance:"substrate"
(SENT
  (S
    (NP-SBJ (PRP:[1510..1512] We))
    (VP (VBP:[1513..1517] have)
      (VP
        (VP (VBN:[1518..1525] mutated)
          (NP=1 (NN:[1526..1530] F116) (CC:[1531..1534] and)
                (NN:[1535..1539] F134))
          (S-PRP=2
            (NP-SBJ (-NONE-:[1539..1539] *))
            (VP (TO:[1540..1542] to)
              (VP (VB:[1543..1552] determine)
                (SBAR (IN:[1553..1555] if)
                  (S
                    (NP-SBJ (PRP:[1556..1560] they))
                    (VP (VBP:[1561..1564] are)
                      (ADJP-PRD (JJ:[1565..1572] present))
                      (PP (IN:[1573..1575] in)
                        (NP (DT:[1576..1579] the) (NN:[1580..1584] heme)
                            (NN:[1586..1592] pocket))))))))))
        (,:[1592..1593] ,) (CC:[1594..1597] and)
        (VP
          (NP=1 (NN:[1598..1602] Q225) (CC:[1603..1606] and)
                (NN:[1607..1611] L228))
          (S-PRP=2
            (NP-SBJ (-NONE-:[1611..1611] *))
            (VP (TO:[1612..1614] to)
              (VP (VB:[1615..1624] determine)
                (SBAR (IN:[1625..1627] if)
                  (S
                    (NP-SBJ (PRP:[1628..1632] they))
                    (VP (VBP:[1633..1636] are)
                      (NP-PRD
                        (NP (DT:[1637..1638] a) (NN:[1639..1643] part))
                        (PP (IN:[1644..1646] of)
                          (NP (DT:[1647..1650] the) (NN:[1651..1660] substrate)
                              (NN:[1662..1673] recognition)
                              (NN:[1674..1678] loop)))))))))))))
    (.:[1678..1679] .)))

;sentence 9 Span:1680..1927
;Although F116E is essentially inactive and may be a folding  mutant or may
;inhibit reductase binding, F134E is more active than the wild type  and may
;be located in the heme pocket facilitating the hydrogen abstraction from  C2
;of androstenedione.
;[1763..1772]:substance:"reductase"
;[1911..1926]:substance:"androstenedione"
(SENT
  (S
    (SBAR-ADV (IN:[1680..1688] Although)
      (S
        (NP-SBJ (NN:[1689..1694] F116E))
        (VP
          (VP (VBZ:[1695..1697] is)
            (ADJP-PRD (RB:[1698..1709] essentially) (JJ:[1710..1718] inactive)))
          (CC:[1719..1722] and)
          (VP
            (VP (MD:[1723..1726] may)
              (VP (VB:[1727..1729] be)
                (NP-PRD (DT:[1730..1731] a) (VBG:[1732..1739] folding)
                        (NN:[1741..1747] mutant))))
            (CC:[1748..1750] or)
            (VP (MD:[1751..1754] may)
              (VP (VB:[1755..1762] inhibit)
                (NP (NN:[1763..1772] reductase) (NN:[1773..1780] binding))))))))
    (,:[1780..1781] ,)
    (NP-SBJ (NN:[1782..1787] F134E))
    (VP
      (VP (VBZ:[1788..1790] is)
        (ADJP-PRD
          (ADJP (RBR:[1791..1795] more) (JJ:[1796..1802] active))
          (PP (IN:[1803..1807] than)
            (NP (DT:[1808..1811] the) (JJ:[1812..1816] wild)
                (NN:[1817..1821] type)))))
      (CC:[1823..1826] and)
      (VP (MD:[1827..1830] may)
        (VP (VB:[1831..1833] be)
          (VP (VBN:[1834..1841] located)
            (NP (-NONE-:[1841..1841] *))
            (PP-LOC (IN:[1842..1844] in)
              (NP
                (NP (DT:[1845..1848] the) (NN:[1849..1853] heme)
                    (NN:[1854..1860] pocket))
                (VP (VBG:[1861..1873] facilitating)
                  (NP
                    (NP (DT:[1874..1877] the) (NN:[1878..1886] hydrogen)
                        (NN:[1887..1898] abstraction))
                    (PP (IN:[1899..1903] from)
                      (NP
                        (NP (NN:[1905..1907] C2))
                        (PP (IN:[1908..1910] of)
                          (NP (NN:[1911..1926] androstenedione)))))))))))))
    (.:[1926..1927] .)))

;sentence 10 Span:1928..2035
;Mutations at Q225 and L228 also result in the anticipated  changes in the
;apparent Km and maximum velocity.
;[2011..2013]:quantitative-name:"Km"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1928..1937] Mutations))
      (PP-LOC (IN:[1938..1940] at)
        (NP (NN:[1941..1945] Q225) (CC:[1946..1949] and) (NN:[1950..1954] L228))))
    (ADVP (RB:[1955..1959] also))
    (VP (VBP:[1960..1966] result)
      (PP-CLR (IN:[1967..1969] in)
        (NP
          (NP (DT:[1970..1973] the) (VBN:[1974..1985] anticipated)
              (NNS:[1987..1994] changes))
          (PP (IN:[1995..1997] in)
            (NP
              (NP (DT:[1998..2001] the) (JJ:[2002..2010] apparent)
                  (NN:[2011..2013] Km))
              (CC:[2014..2017] and)
              (NP (JJ:[2018..2025] maximum) (NN:[2026..2034] velocity)))))))
    (.:[2034..2035] .)))

;section 11 Span:2035..2069
;(ABSTRACT TRUNCATED AT 250  WORDS)
(SEC
  (FRAG (-LRB-:[2035..2036] -LRB-) (NN:[2036..2044] ABSTRACT)
        (VBN:[2045..2054] TRUNCATED) (IN:[2055..2057] AT) (CD:[2058..2061] 250)
        (NNS:[2063..2068] WORDS) (-RRB-:[2068..2069] -RRB-)))

;section 12 Span:2073..2117
;PMID: 8145767 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2073..2077] PMID) (::[2077..2078] :) (CD:[2079..2086] 8145767)
        (NN:[2087..2088] -LSB-) (NNP:[2088..2094] PubMed) (::[2095..2096] -)
        (NN:[2097..2104] indexed) (IN:[2105..2108] for)
        (NNP:[2109..2117] MEDLINE-RSB-)))
